Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 14/20 | 0.54 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23902102 | 0.95 | NISCH (0.50) | NISCHPPARGACHE | |
| SCHEMBL23901858 | 0.92 | NISCH (0.53) | NISCHPPARG | |
| SCHEMBL23901771 | 0.86 | NISCH (0.55) | NISCHACHEMAOAMAOBLMNA | |
| SCHEMBL23902290 | 0.81 | NISCH (0.50) | NISCHACHE | |
| SCHEMBL23902114 | 0.79 | NISCH (0.67) | NISCHMAOAMAOBLMNARECQL | |
| SCHEMBL23901774 | 0.78 | NISCH (0.53) | NISCHACHE | |
| SCHEMBL23901780 | 0.76 | FDPS (0.47) | NISCHACHELMNA | |
| SCHEMBL23902307 | 0.74 | NISCH (0.60) | NISCHLMNARECQL | |
| SCHEMBL14519333 | 0.74 | NISCH (0.56) | NISCHMAOB | |
| SCHEMBL5476725 | 0.74 | NISCH (0.79) | NISCHLMNARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | PAM, AMPD1, AMPD3 | NISCH 24/4885PPARG 2136/4885ACHE 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.